This activity is jointly provided by Postgraduate Institute for Medicine and HealthmattersCME.
This activity is supported by an independent educational grant from Provention Bio.
This program will educate HCPs about the importance of identifying children and adolescents at high risk for T1D before it manifests clinically and mitigate subsequent longer-term complications. Early screening for T1D also may delay the underlying autoantibody-mediated loss of cells when effective interventions become available.
This activity is intended for pediatricians, endocrinologists and primary care physicians engaged in the care of patients with T1D or with the risk of developing T1D.
Upon conclusion of this educational initiative, participants will be better able to:
Identify persons at high risk for developing type 1 diabetes before the onset of clinically detectable disease
Apply a staging classification system for presymptomatic type 1 diabetes to identify persons at high risk for developing this disease to support subsequent potential preventive as well as therapeutic interventions
Utilize the results of recently reported clinical trials of anti-CD3 mAbs to potentially alter the progression of Stage 1 or 2 preclinical type 1 diabetes to Stage 3 clinical type 1 diabetes
Refer patients with recent-onset type 1 diabetes for immune interventions that potentially may delay further decline in β-cell function and thereby possibly improve clinical outcomes
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Professor, Departments of Pathology and Pediatrics
University of Florida College of Medicine
Gainesville, FL
Consulting Fees: Actobio, Akston Biosciences, Cogen Therapeutics, Diamyd Medical, Forkhead Biotherapeutics, Nirminidas, One Vax, Viela Bio Ownership Interest (less than 5%): Diamyd Medical, Nirmindas, IM Therapeutics
Professor of Clinical Diabetes and Metabolism
Cardiff University School of Medicine
Professor of Endocrinology and Diabetes
University of Bristol
United Kingdom
Consulting Fees: Provention Bio
Fees for Non-CE Services: AstraZeneca, MSD
Professor of Pediatrics
University of South Florida
Clinical Director USF Diabetes & Endocrinology Center
Tampa, FL
Consulting Fees: Mannkind, Provention Bio
Fees for Non-CE Services: Provention Bio
Contracted Research: Boehringer, Dexcom, Intrexon, Eli Lilly, Mannkind, Novo, Takeda, Tolerion
Other (DSMB): Merck, Novo
Associate Professor of Pediatrics
Barbara Davis Center at the University of Colorado
Aurora, CO
Contracted Research: Provention Bio, Helmsley Foundation, Janssen, JDRF
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HealthmattersCME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee for this educational activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to obtain your CME certificate, please follow the steps below at the conclusion of the activity:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Name of Planner or Manager | Reported Financial Relationship |
|---|---|
| PIM Planners and Managers | Nothing to disclose |
| HMC Planners and Managers | Nothing to disclose |